Tag: Cdk4 6 inhibitor

In the monarchE clinical trial for high-risk early breast cancer, adding Verzenio to hormone therapy for two years reduced the risk of cancer recurrence by 35% compared to hormone therapy alone [1.3.3]. This article explains how many years you can take Verzenio for based on your diagnosis.

Approved by the FDA in February 2021, trilaciclib is a novel drug for cancer care. So, **what type of drug is trilaciclib?** It is the first-in-class myeloprotection agent, designed to decrease the incidence of chemotherapy-induced bone marrow suppression.

According to the monarchE trial, adding abemaciclib to standard hormone therapy significantly reduced the risk of invasive disease recurrence by over 25% for patients with high-risk, HR+, HER2- early breast cancer. Abemaciclib (brand name Verzenio) is a targeted cancer therapy that has revolutionized treatment for this specific patient population.